Hallucinogen Use Disorders Among Adult Users of MDMA and Other Hallucinogens

REFERENCES

• Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, Substance Abuse and Mental Health Services, Rockville, Md. 2007
   Google Scholar
• National Institute on Alcohol Abuse and Alcoholism. National Epidemiologic Survey on Alcohol and Related Conditions, Survey Questionnaire Index, Wave 1. 2007, Available at: http://niaaa.census.gov/questionaire.html Accessed October 15, 2007
   Google Scholar
• Cregg M T, Tracey J A. Ecstasy abuse in Ireland. Ir Med J 1993; 86: 118–120
   PubMedGoogle Scholar
• Patel M M, Wright D W, Ratcliff J J, Miller M A. Shedding new light on the “safe” club drug: Methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med 2004; 11: 208–210
   PubMed Web of Science ®Google Scholar
• Schifano F, Oyefeso A, Corkery J, et al. Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996–2002. Hum Psychopharmacol 2003; 18: 519–524
   PubMed Web of Science ®Google Scholar
• Schuster P, Lieb R, Lamertz C, Wittchen H U. Is the use of ecstasy and hallucinogens increasing? Results from a community study. Eur Addict Res 1998; 4: 75–82
   PubMed Web of Science ®Google Scholar
• Wilkins C, Bhatta K, Pledger M, Casswell S. Ecstasy use in New Zealand: Findings from the 1998 and 2001 National Drug Surveys. N Z Med J 2003; 116: U383
   PubMedGoogle Scholar
• Substance Abuse and Mental Health Services Administration. Club Drugs, 2001 Update. Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, Md. 2001
   Google Scholar
• Johnston L D, O'Malley P M, Bachman J G, Schulenberg J E. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings. National Institute on Drug Abuse, Bethesda, Md. 2007, NIH Publication No. 07-6202
   Google Scholar
• Montoya A G, Sorrentino R, Lukas S E, Price B H. Long-term neuropsychiatric consequences of “ecstasy” (MDMA): A review. Harv Rev Psychiatry 2002; 10: 212–220
   PubMed Web of Science ®Google Scholar
• Parrott A C. Human psychopharmacology of ecstasy (MDMA): A review of 15 years of empirical research. Hum Psychopharmacol 2001; 16: 557–577
   PubMed Web of Science ®Google Scholar
• National Institute on Drug Abuse. MDMA (Ecstasy) Abuse. 2006, Available at: http://www.drugabuse.gov/PDF/RRmdma.pdf NIDA Research Report Series. Accessed October 15, 2007
   Google Scholar
• Gudelsky G A, Yamamoto B K. Actions of 3,4-methylenedi-oxymethamphetamine (MDMA) on cerebral dopamineric, serotonergic and cholinergic neurons. Pharmacol Biochem Behav 2008; 90: 198–207, [E-pub]
   PubMed Web of Science ®Google Scholar
• Reneman L, Booij J, Majoie C B, Van Den Brink W, Den Heeten G J. Investigating the potential neurotoxicity of ecstasy (MDMA): An imaging approach. Hum Psychopharmacol 2001; 16: 579–588
   PubMed Web of Science ®Google Scholar
• Klugman A, Gruzelier J. Chronic cognitive impairment in users of ‘ecstasy’ and cannabis. World Psychiatry 2003; 2: 184–190
   PubMedGoogle Scholar
• Boyd C J, McCabe S E, d'Arcy H. Ecstasy use among college undergraduates: Gender, race and sexual identity. J Subst Abuse Treat 2003; 24: 209–215
   PubMed Web of Science ®Google Scholar
• Klitzman R L, Greenberg J D, Pollack L M, Dolezal C. MDMA (‘ecstasy’) use, and its association with high risk behaviors, mental health, and other factors among gay/bisexual men in New York City. Drug Alcohol Depend 2002; 66: 115–125
   PubMed Web of Science ®Google Scholar
• Strote J, Lee J E, Wechsler H. Increasing MDMA use among college students: Results of a national survey. J Adolesc Health 2002; 30: 64–72
   PubMed Web of Science ®Google Scholar
• Baker A, Kochan N, Dixon J, Wodak A, Heather N. Drug use and HIV risk-taking behaviour among injecting drug users not currently in treatment in Sydney, Australia. Drug Alcohol Depend 1994; 34: 155–160
   PubMed Web of Science ®Google Scholar
• Rickert V I, Siqueira L M, Dale T, Wiemann C M. Prevalence and risk factors for LSD use among young women. J Pediatr Adolesc Gynecol 2003; 16: 67–75
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text rev. American Psychiatric Association, Washington, DC 2000
   Google Scholar
• Anthony J C, Warner L A, Kessler R C. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994; 2: 244–268
   Web of Science ®Google Scholar
• Compton W M, Conway K P, Stinson F S, Colliver J D, Grant B F. Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: Results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2005; 66: 677–685
   PubMed Web of Science ®Google Scholar
• Grant B F. DSM-IV, DSM-III-R, and ICD-10 alcohol and drug abuse/harmful use and dependence, United States, 1992: A nosological comparison. Alcohol Clin Exp Res 1996; 20: 1481–1488
   PubMed Web of Science ®Google Scholar
• Stone A L, Storr C L, Anthony J C. Evidence for a hallucinogen dependence syndrome developing soon after onset of hallucinogen use during adolescence. Int J Methods Psychiatr Res 2006; 15: 116–130
   Google Scholar
• Pedersen W, Skrondal A. Ecstasy and new patterns of drug use: A normal population study. Addiction 1999; 94: 1695–1706
   PubMed Web of Science ®Google Scholar
• Topp L, Hando J, Dillon P, Roche A, Solowij N. Ecstasy use in Australia: Patterns of use and associated harm. Drug Alcohol Depend 1999; 55: 105–115
   PubMed Web of Science ®Google Scholar
• Yacoubian G S, Jr. Correlates of ecstasy use among students surveyed through the 1997 College Alcohol Study. J Drug Educ 2003; 33: 61–69
   PubMed Web of Science ®Google Scholar
• Cottler L B, Womack S B, Compton W M, Ben-Abdallah A. Ecstasy abuse and dependence among adolescents and young adults: Applicability and reliability of DSM-IV criteria. Hum Psychopharmacol 2001; 16: 599–606
   PubMed Web of Science ®Google Scholar
• Saunders J B. Substance dependence and non-dependence in the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Classification of Diseases (ICD): Can an identical conceptualization be achieved?. Addiction 2006; 101: 48–58
   Google Scholar
• Degenhardt L, Lynskey M, Coffey C, Patton G. ‘Diagnostic orphans’ among young adult cannabis users: Persons who report dependence symptoms but do not meet diagnostic criteria. Drug Alcohol Depend 2002; 67: 205–212
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2005 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, Substance Abuse and Mental Health Services, Rockville, Md. 2006
   Google Scholar
• Turner C F, Ku L, Rogers S M, Lindberg L D, Pleck J H, Sonenstein F L. Adolescent sexual behavior, drug use, and violence: Increased reporting with computer survey technology. Science 1998; 280: 867–873
   PubMed Web of Science ®Google Scholar
• Shiffman S, Waters A J, Hickcox M. The Nicotine Dependence Syndrome Scale: A multi-dimensional measure of nicotine dependence. Nicotine Tob Res 2004; 6: 327–348
   PubMed Web of Science ®Google Scholar
• Fagerstrom K O. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978; 3: 235–241
   PubMed Web of Science ®Google Scholar
• Heatherton T F, Kozlowski L T, Frecker R C, Fagerstrom K O. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction 1991; 86: 1119–1127
   PubMedGoogle Scholar
• Kessler R C, Chiu W T, Demler O, Merikangas K R, Walters E E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617–627
   PubMed Web of Science ®Google Scholar
• Wu L T, Schlenger W E, Galvin D M. Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths. Drug Alcohol Depend 2006; 84: 102–113
   PubMed Web of Science ®Google Scholar
• Wu L T, Pilowsky D J, Wechsberg W M, Schlenger W E. Injection drug use among stimulant users in a national sample. Am J Drug Alcohol Abuse 2004; 30: 61–83
   PubMed Web of Science ®Google Scholar
• Wu L T, Pilowsky D J, Patkar A A. Non-prescribed use of pain relievers among adolescents in the United States. Drug Alcohol Depend 2008; 94: 1–11
   PubMed Web of Science ®Google Scholar
• Research Triangle Institute. SUDAAN User's Manual, Release 9.0. Research Triangle Institute, Research Triangle Park, NC 2006
   Google Scholar
• Hasin D S, Hatzenbueler M, Smith S, Grant B F. Co-occurring DSM-IV drug abuse in DSM-IV drug dependence: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2005; 80: 117–123
   PubMed Web of Science ®Google Scholar
• Helzer J E, van den Brink W, Guth S E. Should there be both categorical and dimensional criteria for the substance use disorders in DSM-V?. Addiction 2006; 101: 17–22
   PubMed Web of Science ®Google Scholar
• Jansen K L. Ecstasy (MDMA) dependence. Drug Alcohol Depend 1999; 53: 121–124
   PubMed Web of Science ®Google Scholar
• Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology (Berl) 2004; 173: 398–404
   PubMed Web of Science ®Google Scholar
• Lieb R, Schuetz C G, Pfister H, von Sydow K, Wittchen H. Mental disorders in ecstasy users: A prospective-longitudinal investigation. Drug Alcohol Depend 2002; 68: 195–207
   PubMed Web of Science ®Google Scholar
• Medina K L, Shear P K. Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: Contributions of polydrug use. Drug Alcohol Depend 2007; 87: 303–311
   PubMed Web of Science ®Google Scholar
• Soar K, Turner J J, Parrott A C. Problematic versus non-problematic ecstasy/MDMA use: The influence of drug usage patterns and pre-existing psychiatric factors. J Psychopharmacol 2006; 20: 417–424
   Web of Science ®Google Scholar
• Hendrickson J C, Gerstein D R. Criminal involvement among young male ecstasy users. Subst Use Misuse 2005; 40: 1557–1575
   PubMed Web of Science ®Google Scholar
• Gfroerer J, Wright D, Kopstein A. Prevalence of youth substance use: The impact of methodological differences between two national surveys. Drug Alcohol Depend 1997; 47: 19–30
   PubMed Web of Science ®Google Scholar
• Thomasius R, Petersen K U, Zapletalova P, Wartberg L, Zeichner D, Schmoldt A. Mental disorders in current and former heavy ecstasy (MDMA) users. Addiction 2005; 100: 1310–1319
   PubMed Web of Science ®Google Scholar
• Baggott M, Heifets B, Jones R T, Mendelson J, Sferios E, Zehnder J. Chemical analysis of ecstasy pills. JAMA 2000; 284: 2190
   PubMed Web of Science ®Google Scholar
• Parrott A C. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl) 2004; 173: 234–241
   PubMed Web of Science ®Google Scholar